Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
130 hedge funds and large institutions have $952M invested in Day One Biopharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 56 increasing their positions, 35 reducing their positions, and 22 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 35
5% more call options, than puts
Call options by funds: $813K | Put options by funds: $775K
1% more capital invested
Capital invested by funds: $941M → $952M (+$10.5M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 140 → 130 (-10)
17.95% less ownership
Funds ownership: 107.12% → 89.17% (-18%)
41% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$14.7M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$14.1M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.39M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.8M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$4.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$20M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$18.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$9.98M |
| 4 |
Goldman Sachs
New York
|
-$9.74M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.76M |
DAWN Hedge Fund Activity: Q3 2023 in Review
130 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q3 2023, worth a combined $952M — up 1.1% from $941M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of DAWN and 13 opened new positions — a net loss of 9 holders — while 35 trimmed existing stakes and 56 added.
The largest buyer was BlackRock, adding an estimated $14.7M. The largest seller was Fidelity Investments, cutting an estimated $20M.
- 130 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q3 2023, down from 140 in Q2 2023.
- Funds reported $952M of Day One Biopharmaceuticals stock for Q3 2023, up 1.1% quarter-over-quarter.
- 13 funds opened new Day One Biopharmaceuticals positions in Q3 2023 and 22 closed out, a net change of -9 holders.
- The largest Day One Biopharmaceuticals buyer in Q3 2023 was BlackRock, an estimated $14.7M added.
- The largest Day One Biopharmaceuticals seller in Q3 2023 was Fidelity Investments, an estimated $20M sold.
Based on aggregated 13F filings for Q3 2023.